Bepotastine Besilate Patent Expiration
Bepotastine Besilate was first introduced by Bausch And Lomb Inc
Bepotastine Besilate Patents
Given below is the list of patents protecting Bepotastine Besilate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bepreve | US6780877 | Acid addition salt of optically active piperidine compound and process for preparing the same |
Sep 19, 2019
(Expired) | Bausch And Lomb Inc |
| Bepreve | US8784789 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | Jan 13, 2025 | Bausch And Lomb Inc |
| Bepreve | US8877168 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul 30, 2023
(Expired) | Bausch And Lomb Inc |
Explore Our Curated Drug Screens
Bepotastine Besilate Generics
Several generic applications have been filed for Bepotastine Besilate. The first generic version for Bepotastine Besilate was by Apotex Inc and was approved on Mar 5, 2019. And the latest generic version is by Alembic Pharmaceuticals Ltd and was approved on Apr 5, 2023.
Given below is the list of companies who have filed for Bepotastine Besilate generic.
1. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Apr 5, 2023 |
2. APOTEX
Apotex Inc has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 5, 2019 |
3. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Bepotastine Besilate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5% | solution/drops | Prescription | OPHTHALMIC | AT | Mar 18, 2019 |